
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion Inc has demonstrated significant revenue growth, with a reported Q3 revenue increase of 31% year-over-year driven primarily by an 89% rise in Nociscan report volumes, indicating strong market demand for its healthcare technology solutions. The company's proactive approach to expand its sales and marketing efforts, including strategic partnerships with several medical institutions, positions it well for continued growth, particularly as it navigates favorable coverage decisions in the UK. Furthermore, the sustained momentum in scan volumes, exemplified by 132% year-over-year growth reported in Q2, reinforces a positive outlook on the company's financial trajectory as it seeks to optimize clinical treatments through its innovative SaaS platform, Nociscan.
Bears say
Aclarion Inc faces significant challenges which contribute to a negative outlook on its stock. The company is experiencing slower-than-expected traction with both surgeons and payers, combined with higher than anticipated marketing and administrative expenses, which is reflected in the downward adjustments of its FY25 EPS estimates. Furthermore, risks related to balance sheet liquidity, regulatory approvals, product commercialization, and the need for reimbursement add further pressure on the company's financial stability.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares